CT-4201
Pharmaceutical compound
From Wikipedia, the free encyclopedia
CT-4201 is a serotonergic psychedelic which is under development for the treatment of major depressive disorder.[1][2][3] It is a prodrug of the tryptamine psychedelic psilocin that is said to have improved pharmacokinetic properties compared to psilocybin, the primary active constituent of psilocybin-containing mushrooms.[1][2][3][4][5] CT-4201 is being developed by CaaMTech.[1][2][3] As of November 2024, it is in the preclinical research stage of development.[1][2]
Other namesCT4201
Drug classNon-selective serotonin receptor agonist; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen
ATC code
- None
| Clinical data | |
|---|---|
| Other names | CT4201 |
| Drug class | Non-selective serotonin receptor agonist; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen |
| ATC code |
|
See also
- Substituted tryptamine
- List of investigational hallucinogens and entactogens
- EB-002, MSP-1014, RE-109 (4-GO-DMT)
- Luvesilocin (4-GO-DiPT)
